We applied this sample clustering approach across 100 breast cancer IMC samples and found remarkable concordance with clinical metrics such as ER status and ERBB2-positive patients, even though we used only 37 protein markers (Fig. 6). Here, ERBB2 is linked to breast carcinoma.